# Beta-Lactam Containing Regimen for the Shortening of Buruli Ulcer Disease Therapy

> **NCT05169554** · PHASE2 · RECRUITING · sponsor: **Fundacion Agencia Aragonesa para la Investigacion y Desarrollo (ARAID)** · enrollment: 140 (estimated)

## Conditions studied

- Buruli Ulcer

## Interventions

- **DRUG:** Standard [RC8]: rifampicin plus clarithromycin (RC) therapy for 8 weeks.
- **DRUG:** Investigational [RCA4]: standard (RC) plus amoxicillin/clavulanate (A) for 4 weeks.

## Key facts

- **NCT ID:** NCT05169554
- **Lead sponsor:** Fundacion Agencia Aragonesa para la Investigacion y Desarrollo (ARAID)
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-12-01
- **Primary completion:** 2026-05-31
- **Final completion:** 2026-05-31
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2024-05-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05169554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05169554, "Beta-Lactam Containing Regimen for the Shortening of Buruli Ulcer Disease Therapy". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05169554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*